HIV related and non-HIV related mortality before and after the introduction of highly active antiretroviral therapy (HAART) in Norway compared to the general population

References

• Palella FJ, Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853–60
   PubMed Web of Science ®Google Scholar
• Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, et al. AIDS across Europe, 1994–98: the EuroSIDA study. Lancet 2000; 356: 291–6
   PubMed Web of Science ®Google Scholar
• McNaghten AD, Hanson DL, Jones JL, Dworkin MS, Ward JW. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group. AIDS 1999; 13: 1687–95
   PubMed Web of Science ®Google Scholar
• Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16: 1663–71
   PubMed Web of Science ®Google Scholar
• Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135: 17–26
   PubMed Web of Science ®Google Scholar
• Jaggy C, Von Overbeck J, Ledergerber B, Schwarz C, Egger M, Rickenbach M, et al. Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. Lancet 2003; 362: 877–8
   PubMed Web of Science ®Google Scholar
• Jensen-Fangel S, Pedersen L, Pedersen C, Larsen CS, Tauris P, Moller A, et al. Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population. AIDS 2004; 18: 89–97
   PubMed Web of Science ®Google Scholar
• Keiser O, Taffe P, Zwahlen M, Battegay M, Bernasconi E, Weber R, et al. All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population. AIDS 2004; 18: 1835–43
   PubMedGoogle Scholar
• Lewden C, Raffi F, Chene G, Sobel A, Leport C. Mortality in a cohort of HIV-infected adults started on a protease inhibitor-containing therapy: standardization to the general population. J Acquir Immune Defic Syndr 2001; 26: 480–2
   PubMedGoogle Scholar
• Wang C, Vlahov D, Galai N, Bareta J, Strathdee SA, Nelson KE, et al. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis 2004; 190: 1046–54
   PubMed Web of Science ®Google Scholar
• Statistics Norway. Available at:, , http://www.ssb.no.
   Google Scholar
• 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41:1–19.
   PubMedGoogle Scholar
• Chiang CL. The life table and its applications. Robert E. Krieger Publishing Company, Malabar 1984
   Google Scholar
• Jain MK, Skiest DJ, Cloud JW, Jain CL, Burns D, Berggren RE. Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999–2000. Clin Infect Dis 2003; 36: 1030–8
   PubMed Web of Science ®Google Scholar
• Morgello S, Mahboob R, Yakoushina T, Khan S, Hague K. Autopsy findings in a human immunodeficiency virus-infected population over 2 decades: influences of gender, ethnicity, risk factors, and time. Arch Pathol Lab Med 2002; 126: 182–90
   PubMed Web of Science ®Google Scholar
• Selik RM, Byers RH, Jr, Dworkin MS. Trends in diseases reported on US death certificates that mentioned HIV infection, 1987–1999. J Acquir Immune Defic Syndr 2002; 29: 378–87
   PubMed Web of Science ®Google Scholar
• Valdez H, Chowdhry TK, Asaad R, Woolley IJ, Davis T, Davidson R, et al. Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995–1999. Clin Infect Dis 2001; 32: 1487–93
   PubMed Web of Science ®Google Scholar
• Norwegian Institute of Public Health. Available at:, , http://www.fhi.no.
   Google Scholar
• Copeland L, Budd J, Robertson JR, Elton RA. Changing patterns in causes of death in a cohort of injecting drug users, 198–2001. Arch Intern Med 2004; 164: 1214–20
   PubMedGoogle Scholar
• Vlahov D, Wang CL, Galai N, Bareta J, Mehta SH, Strathdee SA, et al. Mortality risk among new onset injection drug users. Addiction 2004; 99: 946–54
   PubMed Web of Science ®Google Scholar
• Lewden C, Bonnet F, Bevilacqua S, Heripret L, May T, Morlat P, et al. Causes of death in HIV-infected French drug users, 1995–2000. Ann Med Interne (Paris) 2002; 153(Suppl 7)S4–10
   Google Scholar
• Marimoutou C, Poizot-Martin I, Loundou AD, Cassuto JP, Obadia Y. Causes of hospitalization and death in the MANIF 2000 cohort, composed of HIV-infected patients contaminated by intravenous drug use, 1995–1999. Presse Med 2003; 32: 587–94
   PubMedGoogle Scholar
• Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492–7
   PubMed Web of Science ®Google Scholar
• Macias J, Melguizo I, Fernandez-Rivera FJ, Garcia-Garcia A, Mira JA, Ramos AJ, et al. Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV infected patients receiving potent antiretroviral therapy. Eur J Clin Microbiol Infect Dis 2002; 21: 775–81
   PubMed Web of Science ®Google Scholar
• Rosenthal E, Poiree M, Pradier C, Perronne C, Salmon-Ceron D, Geffray L, et al. Mortality due to hepatitis C-related liver disease in HIV infected patients in France (Mortavic 2001 study). AIDS 2003; 17: 1803–9
   PubMed Web of Science ®Google Scholar